Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
sorry that should have said what happened with iclaprim Arpida and Evolva.
Midas you’ve not read that correctly.
Arpida. !!! Have only been the subject of one rto
And the reason I say technically 5 times is that Arpida was spun out of Roche with iclaprim
As for the value to share holders what happened with iclaprim and Evolva would be the equivalent of us who hold here losing two thirds of our shares but our remaining shares in the new co trading at 20-30p soon after relisting ..... I think most would take that!
And before you ( or someone else ) comes back with because it happened before doesn’t mean it would happen the same way. Yes I accept that but that the chance you take here.
Pmsl. You say it’s been in 5 companies not including us. Lol. So that’s 6 then. I said 6 or 7.
I’m meaning along with this RTO. Or possible RTO.
Midas.
“That was the start of another RTO of Arpida which didn’t benefit the shareholders but did the BOD. I believe it’s 6 or maybe even 7 companies that have sold Iclaprim now.“
Arpida was only ever the subject of a RTO once ( I’m not sure how you do that twice !!! )
There was benefit to the shareholders I’ve posted the Reuter’s link. If the exact same played out here we would lose two thirds of our holdings that would go to the new co shareholders but would trade at a higher price if it followed the same path as the Evolva /Arpida deal ( I think most holders on here would settle for that ) it’s worth checking out the share price history of Evolva to get an idea of what I mean.
It’s technically been in 5 companies hands not including us Arpida was spun out of Roche and Nuprim had the same people in place as at Roche and Arpida.
I’ll agree there was a “collapse“ in the share price as seen here over the last couple of years that’s a fair point. But another fair point is what happened to the Evolva shares when they started trading from losing virtually all their value as Arpida !!!!
To say they collapsed implies they went bust .... they didn’t they saw a collapse in the share price.
https://www.reuters.com/article/us-arpida-idUSTRE58917E20090910
Yes after the rejection Arpida collapsed ( like Motif ) became a shell followed by a RTO. Which helped the BOD. Not the shareholders.
I think the reminants of Arpida became Evolva after the Rto.
Really? That not how I recall things from my research but it is early so forgive me if I’m not 100% here .... I’m sure you will check.
Roche who discovered the drug originally spun a division out that became Arpida. Arpida sold the drug on and became the Target of an rto ( check out the Lombard Odier connection again here again ) That did in fact benefit the shareholders I believe it was a one third to two third split in the share price but if you had held in to those shares for any j oh engage if time you would have ended up out of pocket but at the time it worked out. Anyway I digress Acino picked the drug up did not hitting with it and passed it to Life sciences management group who again did nothing until Nuprim I believe it was which was formed by a director or the original Arpida team took it on. After this it was sold to Motif.
Worth checking this for accuracy as I’m not at my pc and that’s from memory.
A quick glance back shows it was 2008 / 2009. They did a parallel application to the FDA and the EMA. That’s when they had that famous quote. “ this drug should not be developed further “ from the FDA and a similar result from the EMA. Shortly afterwards that was the end of the company that held Iclaprim back then - Arpida. That was the start of another RTO of Arpida which didn’t benefit the shareholders but did the BOD. I believe it’s 6 or maybe even 7 companies that have sold Iclaprim now.
They did try Europe around 12 years back around the time the FDA first time around rejected Iclaprim.
Potentially it’s of use to any country but as someone said earlier it wasn’t a failure but more information was required before submission.
Iclaprim is owned by motif and Hercules have a perfected security arrangement over it.
Yes some of the same backers and shareholders here’s a list.
https://www.marketscreener.com/CIRCASSIA-GROUP-PLC-16012085/company/
But beyond that I’m not aware of any connection.
Hi all, could someone enlighten myself, with regards to Circassia Group plc and their financial backers and their connection with motif, I am slightly confused, has anyone heard of such a connection ?